ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

ENDONOVO THERAPEUTICS, INC.

Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023

$0.00+0.00 (0.00%)

Close on Oct 19, 2026

Community

Notes and questions about Endonovo Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Endonovo Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-1000 reverse split on Dec 20, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ENDV.

Revenue growth1699.9% · median 23.9%

Gross margin96.2% · median 80.4%

Operating margin-1023.2% · median -21.4%

Net margin-1722.2% · median -26.7%

Advertisement
300 × 250